Nanoliposome-loaded antifungal drugs for dermal administration: A review.

Antifungal Drug delivery Liposome Nanoparticle Skin

Journal

Current medical mycology
ISSN: 2423-3439
Titre abrégé: Curr Med Mycol
Pays: Iran
ID NLM: 101647935

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 01 02 2021
revised: 20 03 2021
accepted: 16 04 2021
entrez: 23 9 2021
pubmed: 24 9 2021
medline: 24 9 2021
Statut: ppublish

Résumé

Cutaneous fungal infections are the fourth most common health problem, which involves approximately one billion people worldwide. Drug delivery to the skin seems to be the best choice for superficial fungal infections. Topical formulations can release a sufficient amount of drug in therapeutical concentrations and permeate higher layers of the skin like the stratum corneum. As the outermost layer of the epidermis, the stratum corneum prevents the drug from penetrating the skin. Liposomes, especially nanosized as topical drug delivery systems to the skin, can show various functions depending on their size, lipids and cholesterol components, the percent of ingredients, lamellarity, and surface charge. Nanoliposomes can increase permeation through the stratum corneum, decrease systemic effects with their localizing actions, and overcome many dermal drug delivery obstacles. Antifungal drugs, such as croconazole, econazole, fluconazole, ketoconazole, terbinafine hydrochloride, tolnaftate, and miconazole entrapped in liposomes have indicated improved skin penetration and localizing effects. According to the literature review summarized in this paper, many studies have identified liposomes as a powerful carrier for topical antifungal drug delivery to the skin. However, a few studies introduced new generations of liposomes like ethosomes and transfersomes. This paper was conducted on almost all liposomal studies of antifungal drugs with dermal application.

Identifiants

pubmed: 34553102
doi: 10.18502/cmm.7.1.6247
pii: CMM-7-1
pmc: PMC8443872
doi:

Types de publication

Journal Article

Langues

eng

Pagination

71-78

Informations de copyright

Copyright: © 2021, Published by Mazandaran University of Medical Sciences on behalf of Iranian Society of Medical Mycology and Invasive Fungi Research Center.

Références

Dermatol Clin. 2007 Apr;25(2):165-83, vi
pubmed: 17430754
Curr Med Mycol. 2015 Dec;1(4):7-12
pubmed: 28680998
Expert Opin Drug Deliv. 2010 Nov;7(11):1303-27
pubmed: 20961206
J Liposome Res. 2010 Dec;20(4):341-50
pubmed: 20163329
J Drug Target. 1999;6(5):361-72
pubmed: 10342384
Eur J Pharm Sci. 2013 Mar 12;48(4-5):628-36
pubmed: 23295582
Curr Med Mycol. 2018 Dec;4(4):31-36
pubmed: 30815615
Pharm Nanotechnol. 2019;7(1):24-38
pubmed: 31092174
J Invest Dermatol. 1984 Feb;82(2):188-94
pubmed: 6693781
Antimicrob Agents Chemother. 1987 Mar;31(3):421-9
pubmed: 3579259
Microbiol Res. 2008;163(1):1-12
pubmed: 18037279
Int J Nanomedicine. 2015 Feb 02;10:975-99
pubmed: 25678787
Mycopathologia. 2017 Feb;182(1-2):5-31
pubmed: 27783317
Asian J Pharm Sci. 2019 Mar;14(2):117-129
pubmed: 32104444
Recent Pat Antiinfect Drug Discov. 2018;13(2):127-150
pubmed: 29807522
Artif Cells Nanomed Biotechnol. 2014 Feb;42(1):32-46
pubmed: 23452349
Eur J Pharm Biopharm. 2003 Nov;56(3):389-92
pubmed: 14602181
Indian J Dermatol Venereol Leprol. 2015 Sep-Oct;81(5):457-63
pubmed: 26261140
Life Sci. 1980 May 5;26(18):1473-7
pubmed: 6893068
Jundishapur J Microbiol. 2016 Jan 09;9(1):e28280
pubmed: 27099684
Lancet. 2012 Dec 15;380(9859):2163-96
pubmed: 23245607
J Pharm Pharmacol. 2006 Apr;58(4):415-29
pubmed: 16597359
Artif Cells Nanomed Biotechnol. 2018 Dec;46(8):2054-2065
pubmed: 29205059
Int J Pharm. 2017 May 15;523(1):15-32
pubmed: 28323096
J Drug Target. 2017 Sep;25(8):685-703
pubmed: 28521529
Int J Pharm. 2015 Nov 10;495(1):599-607
pubmed: 26383840
J Control Release. 2011 Jul 30;153(2):126-32
pubmed: 21397643
J Pharm Pharm Sci. 2004 Jul 16;7(2):252-9
pubmed: 15367383
Eur J Pharm Sci. 2008 Aug 7;34(4-5):203-22
pubmed: 18572392
J Pharm Sci. 2011 Jul;100(7):2911-9
pubmed: 21319163
Pharm Dev Technol. 2012 Nov-Dec;17(6):661-5
pubmed: 21563987
Curr Med Chem. 2018 Feb 13;25(5):606-635
pubmed: 28990515
J Dermatolog Treat. 2019 Sep;30(6):617-626
pubmed: 29856232
Drug Dev Ind Pharm. 2005 May;31(4-5):375-83
pubmed: 16093203
Curr Drug Deliv. 2014;11(4):521-30
pubmed: 24410098
Int J Antimicrob Agents. 2007 Dec;30(6):487-95
pubmed: 17961990
Expert Opin Drug Deliv. 2008 Nov;5(11):1199-216
pubmed: 18976131
Expert Opin Drug Deliv. 2017 Jan;14(1):109-122
pubmed: 27348356
Drug Deliv. 2014 Feb;21(1):34-43
pubmed: 24116896
Carbohydr Polym. 2020 Jul 15;240:116267
pubmed: 32475557
J Mater Sci Mater Med. 2015 Apr;26(4):175
pubmed: 25825320
J Pharm Pharmacol. 1982 Jul;34(7):473-4
pubmed: 6126554
Postgrad Med. 2001 Jan;109(1):117-20, 123-6, 131-2
pubmed: 11198246
P T. 2017 Dec;42(12):742-755
pubmed: 29234213

Auteurs

Peyman Asadi (P)

Student Research Committee, Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Ahmad Mehravaran (A)

Infectious Diseases and Tropical Medicine Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran.

Nahid Soltanloo (N)

Student Research Committee, Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Mahdi Abastabar (M)

Invasive Fungi Research Center/Department of Medical mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Javad Akhtari (J)

Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Toxoplasmosis Research Center, Communicable Diseases Institute, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Classifications MeSH